Janux Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.18
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 563.7M
Operating cash flow -41.49M
ESG Scores unknown

Company description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 4k 8.01M 2k
Total Cashflows From Investing Activities -340.96M -340.96M -340.96M
Net Borrowings 4M 2.5M
Total Cash From Financing Activities 4M 11.52M 386.52M
Change To Operating Activities -73k 375k 840k
Issuance Of Stock 70k 70k 205.98M
Net Income -4M -6.78M -32.67M
Change In Cash 172k 7.16M 28.59M
Effect Of Exchange Rate
Total Cash From Operating Activities -3.83M -4.37M -16.98M
Depreciation 6k 13k 113k
Change To Account Receivables -8M -8M 8M
Other Cashflows From Financing Activities
Change To Netincome 239k 2.01M 6.74M
Capital Expenditures -1.48M -1.48M -1.48M

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 3M
Income Before Tax -4M -6.78M -32.67M
Net Income -4M -6.78M -32.67M
Selling General Administrative 772k 1.8M 10.33M
Gross Profit -3.04M -22.6M
Ebit -3.77M -4.84M -32.93M
Operating Income -3.77M -4.84M -32.93M
Interest Expense -233k -206k
Income Tax Expense
Total Revenue 3.64M
Cost Of Revenue 3.04M 26.24M
Total Other Income ExpenseNet -233k -1.94M 257k
Net Income From Continuing Ops -4M -6.78M -32.67M
Net Income Applicable To Common Shares -4M -6.78M -32.67M

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.63M 9.23M 13.5M
Total Stockholder Equity -7.94M -14.64M 366.33M
Other Current Liabilities 2M 6.37M
Total Assets 679k 16.22M 379.82M
Common Stock 1k 1k 41k
Other Current Assets
Retained Earnings -7.96M -14.74M -47.41M
Treasury Stock -270k
Cash 658k 7.81M 35.58M
Total Current Liabilities 4.63M 3.18M 12.8M
Other Stockholder Equity -270k
Property, Plant, and Equipment 21k 155k 1.6M
Total Current Assets 658k 16.06M 377.02M
Net Tangible Assets -7.94M -14.64M 366.33M
Net Receivables 8M 200k
Accounts Payable 267k 428k 2.46M


Insider Transactions

Here are the insider transactions of stock shares related to Janux Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
THOMPSON PETER ASale at price 20.30 per share.I2021-12-29Director40.4k
ORBIMED ADVISORS, L.L.C.Sale at price 20.30 per share.I2021-12-29Director40.4k
THOMPSON PETER ASale at price 19.00 per share.I2021-12-21Director119.4k
THOMPSON PETER ASale at price 19.07 per share.I2021-12-16Director393.3k
ORBIMED ADVISORS, L.L.C.Sale at price 19.07 per share.I2021-12-16Unknown393.3k
LICHTER JAYPurchase at price 17.00 per share.I2021-06-15Director and Beneficial Owner of more than 10% of a Class of Security629.41k
LICHTER JAYI2021-06-15Director and Beneficial Owner of more than 10% of a Class of Security8.05M
THOMPSON PETER APurchase at price 17.00 per share.I2021-06-15Director705.85k
THOMPSON PETER AI2021-06-15Director2.34M
ORBIMED ADVISORS, L.L.C.Purchase at price 17.00 per share.I2021-06-15Beneficial Owner of more than 10% of a Class of Security705.85k
ORBIMED ADVISORS, L.L.C.I2021-06-15Beneficial Owner of more than 10% of a Class of Security2.34M
RA CAPITAL MANAGEMENT, L.P.Purchase at price 17.00 per share.I2021-06-15Beneficial Owner of more than 10% of a Class of Security2.94M
RA CAPITAL MANAGEMENT, L.P.I2021-06-15Beneficial Owner of more than 10% of a Class of Security5.73M
REARDON TIGHEPurchase at price 17.00 per share.I2021-06-15Chief Financial Officer629.41k
REARDON TIGHEI2021-06-15Chief Financial Officer3.85M
AVALON VENTURES XI, L.P.Purchase at price 17.00 per share.I2021-06-15Beneficial Owner of more than 10% of a Class of Security629.41k
AVALON VENTURES XI, L.P.I2021-06-15Beneficial Owner of more than 10% of a Class of Security8.05M
BREGUA CORPPurchase at price 17.00 per share.I2021-06-15Beneficial Owner of more than 10% of a Class of Security58.82k
BREGUA CORPI2021-06-15Beneficial Owner of more than 10% of a Class of Security3.69M

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Janux Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Janux Therapeutics Inc

Here is the result of two systematic investment strategies applied to Janux Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Janux Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Janux Therapeutics Inc:

Janux Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -17.93% on the backtest period.

Performance at glance

Performance

-17.93 %

Latent gain

-44.19 $

Invested capital

246.51 $

Annualized return

-40.75 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Janux Therapeutics Inc

This is the result of two momentum investment strategies applied to Janux Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Janux Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Janux Therapeutics Inc:

Janux Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -14.68% of return on Janux Therapeutics Inc. That represents -73.48$ of latent gain with 500.6$ of employed capital.
  • The second momentum investment strategy would give 0% of return on Janux Therapeutics Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-14.68 %

Latent gain

-73.48 $

Invested capital

500.6 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on Janux Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Janux Therapeutics Inc:

Janux Therapeutics Inc momentum equity

Note: the dividends potentially given by Janux Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Janux Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Janux Therapeutics Inc since the beginning:

Janux Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Janux Therapeutics Inc

Buy the dip entry openings on Janux Therapeutics Inc

Janux Therapeutics Inc

The performance achieved by the robo-advisor on Janux Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Janux Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Janux Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to Janux Therapeutics Inc

The following chart shows the result of the investment strategy applied to Janux Therapeutics Inc:

Janux Therapeutics Inc

Note: the dividends potentially given by Janux Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Janux Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Janux Therapeutics Inc:

Janux Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Janux Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Janux Therapeutics Inc.

Equity curve comparison on Janux Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Janux Therapeutics Inc investment strategy comparison

Employed capital comparison on Janux Therapeutics Inc

Janux Therapeutics Inc investment comparison

Performance comparison on Janux Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -17.93% -44.19$ 246.51$ -40.75%
Momentum 1 quarter -14.68% -73.48$ 500.6$ -73.4%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

-40.75 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Janux Therapeutics Inc:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Janux Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Janux Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Janux Therapeutics Inc
Country United States
City La Jolla
Address 11099 North Torrey Pines Road
Phone 858 750 4700
Website www.januxrx.com
FullTime employees 56
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker JANX
Market www.nasdaq.com

Janux Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown